SCHEMBL5743522

SCHEMBL5743522

C[C@H](N)C(O)c1ccc(F)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.61
LMNA P02545 4/20 0.61
HIF1A Q16665 3/20 0.61
ADRA2A P08913 1/20 0.61
ADRA2C P18825 1/20 0.61
ALDH1A1 P00352 1/20 0.59
RECQL P46063 4/20 0.53
TDP1 Q9NUW8 4/20 0.53
MAPT P10636 3/20 0.53
ALOX15 P16050 1/20 0.53
TSHR P16473 1/20 0.53
NFKB1 P19838 1/20 0.53
THPO P40225 1/20 0.53
HSD17B10 Q99714 1/20 0.53
POLB P06746 1/20 0.53
APEX1 P27695 1/20 0.53
MTOR P42345 1/20 0.53
BLM P54132 1/20 0.53
KMT2A Q03164 1/20 0.53
ADRB1 P08588 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11414917 1.00 KDM4E (0.61) KDM4ELMNAHIF1AADRA2AADRA2C
SCHEMBL31620153 1.00 KDM4E (0.61) KDM4ELMNAHIF1AADRA2AADRA2C
SCHEMBL10305427 1.00 KDM4E (0.61) KDM4ELMNAHIF1AADRA2AADRA2C
SCHEMBL7650052 1.00 KDM4E (0.61) KDM4ELMNAHIF1AADRA2AADRA2C
SCHEMBL15450371 0.81 AOC3 (0.48) KDM4ELMNAHIF1AADRA2AADRA2C
SCHEMBL15050864 0.81 AOC3 (0.44) KDM4ELMNAHIF1AADRA2AADRA2C
SCHEMBL3932318 0.81 AOC3 (0.48) KDM4ELMNAHIF1AADRA2AADRA2C
SCHEMBL14996734 0.81 AOC3 (0.48) KDM4ELMNAHIF1AADRA2AADRA2C
SCHEMBL15050397 0.81 AOC3 (0.44) KDM4ELMNAHIF1AADRA2AADRA2C
SCHEMBL15050395 0.81 AOC3 (0.44) KDM4ELMNAHIF1AADRA2AADRA2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2799431-A1 NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF FUJIFILM Corporation (JP) 2014-11-05 EP disclosed
US-20060252780-A1 Fused pyrimidine derivatives KYOWA HAKKO KOGYO CO., LTD. (JP) 2006-11-09 US disclosed
EP-1637532-A1 FUSED PYRIMIDINE DERIVATIVE KYOWA HAKKO KOGYO CO., LTD. (JP) 2006-03-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060252780-A1 Fused pyrimidine derivatives INSR, GPR119, NPY4R KDM4E 1514/4885LMNA 4671/4885HIF1A 3017/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.